Background:

Fluzinamide is an effective antiepileptic.

Fluzinamide, an antiepileptic agent effective against partial seizures, is metabolized extensively in mice, rats and dogs[1].The anticonvulsant properties of Fluzinamide (AHR-8559) are evaluated in the kindled amygdaloid seizure model in rats. Fluzinamide significantly attenuates afterdischarge durations and the severity of the accompanying convulsive responses in previously kindled rats at doses that does not cause sedation or ataxia. After acute intraperitoneal injections, the maximum anticonvulsant effectiveness against suprathreshold (400 μA) stimulation is seen at 30 min. Fluzinamide (10-80 mg/kg i.p.) is also evaluated in kindled rats using threshold (20 μA increments) seizures. Low doses of Fluzinamide significantly elevate seizure threshold and reduce both elicited after discharge durations and seizure severity. When administered daily during kindling acquisition, Fluzinamide (20 and 40 mg/kg i.p.) significantly increases the number of trials necessary to complete kindling. The duration and the severity of the responses induced by stimulations during the acquisition period are reduced[2].

[1]. Johnson DN, et al. Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. Epilepsy Res. 1990 Apr;5(3):185-91. [2]. Albertson TE, et al. Anticonvulsant action of fluzinamide (AHR-8559) on kindled amygdaloid seizures. Epilepsia. 1984 Aug;25(4):511-7.